Fennec Pharmaceuticals announced last night new research supporting integration and use of PEDMARK at the 2026 ASCO annual meeting

[출처/시간] Briefing.com - 6:13 AM ET, 05/22/2026

Randomized Phase 1 Trial of Cisplatin-Based Chemotherapy With or Without Sodium Thiosulfate for Men with Metastatic Germ Cell Tumor (GCT) Abstract #: TPS5131Dr. Shah will present the trial design for a randomized Phase 1 study of cisplatin-based chemotherapy with or without sodium thiosulfate (PEDMARK) for men with metastatic germ cell tumors (GCT) that was opened to accrual by City of Hope in January of 2026. Among adult GCT survivors, approximately 75 percent develop hearing loss, with severity associated with cumulative cisplatin exposure. Effects of Delayed Sodium Thiosulfate on Cisplatin-Induced Ototoxicity in Pediatric and Adolescent Patients with Cancer: Results from the Japanese Children's Cancer Group STS-J01 Study Abstract #: 10052Detailed results from the investigator-initiated Phase 2/3 STS-J01 clinical trial evaluating PEDMARK for the reduction of CIO in pediatric and AYA patients with non-metastatic solid tumors in Japan will be presented by Eiso Hiyama, MD, professor in the Department of Pediatric Surgery at Hiroshima University Hospital in Hiroshima, Japan. The study, which enrolled 27 patients, met its primary endpoint with a significant reduction in hearing loss in 3--18-year-old patients who received PEDMARK when compared with historically reported rates of hearing loss in patients receiving cisplatin alone (16-24% versus 56-63%, respectively).Real-world Feasibility and Tolerability of PEDMARK for Otoprotection in Young Adults Receiving Cisplatin for Solid Tumors Abstract #: e24189Veronica Alana Vestal, MD, of the Comprehensive Cancer Center of the University of Puerto Rico will share a retrospective case series including nine patients aged 18-39 years old with localized solid tumors that demonstrate that PEDMARK can be feasibly incorporated into AYA and Adult oncology workflows and does not interfere with cisplatin's antitumor activity.